TerrAscend (TSNDF) Liabilities and Shareholders Equity (2021 - 2026)

TerrAscend's (TSNDF) quarterly Liabilities and Shareholders Equity came in at $549.1 million in Q1 2026, down 8.6% year-on-year from $600.7 million in Q1 2025, and down 1.49% on a QoQ basis from $557.4 million in Q4 2025.

TerrAscend (TSNDF) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

TerrAscend (TSNDF) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $549.1 million in Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 8.6% year-over-year to $549.1 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 11.54% decrease from a year earlier, with the FY2025 full-year figure at $557.4 million, down 8.21% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $549.1 million, down from $557.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for TSNDF reached as high as $1.0 billion in Q1 2022 and fell as low as $91000.0 in Q2 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $646.4 million across 5 years, with a median of $656.9 million in 2024.
  • Across the five-year window, Liabilities and Shareholders Equity plunged 99.99% in 2023 and jumped 725442.86% in 2024, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $701.6 million in 2022, then dropped by 5.0% to $666.5 million in 2023, then dropped by 8.9% to $607.2 million in 2024, then decreased by 8.21% to $557.4 million in 2025, then fell by 1.49% to $549.1 million in 2026.
  • Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $549.1 million in Q1 2026, $557.4 million in Q4 2025, and $555.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 TerrAscend 160.44 Mn 162.98 Mn 34.60 Mn 549.10 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 549.10 Mn
Dec 31, 2025 557.38 Mn
Sep 30, 2025 555.26 Mn
Jun 30, 2025 572.01 Mn
Mar 31, 2025 600.73 Mn
Dec 31, 2024 607.23 Mn
Sep 30, 2024 656.93 Mn
Jun 30, 2024 660.24 Mn
Mar 31, 2024 655.54 Mn
Dec 31, 2023 666.52 Mn
Sep 30, 2023 734.67 Mn
Jun 30, 2023 91,000.00
Mar 31, 2023 701.58 Mn
Dec 31, 2022 701.59 Mn
Sep 30, 2022 725.49 Mn
Jun 30, 2022 1.01 Bn
Mar 31, 2022 1.04 Bn
Dec 31, 2021 581.94 Mn